Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
Future Oncol
; 17(4): 403-409, 2021 Feb.
Article
en En
| MEDLINE
| ID: mdl-33028084
ABSTRACT
Aim:
To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials &methods:
Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS).Results:
In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median 6.4 vs 5.9 years; hazard ratio 0.9; 95% CI 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio 0.8; 95% CI 0.6-1.0).Conclusion:
Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration NCT00375674 (ClinicalTrials.gov).Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Plaquetas
/
Linfocitos
/
Carcinoma de Células Renales
/
Neoplasias Renales
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article